A Phase 3 interventional study of HCP1803-3 and HCP1803-4 in Hypertension, sponsored by Hanmi Pharmaceutical Company Limited. Not yet recruiting at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-06-30.
Sponsored by Hanmi Pharmaceutical Company Limited · Phase 3, Interventional, and Treatment
A Study to Evaluate Efficacy and Safety of HCP1803-4 in Patients With Essential Hypertension
A multicenter, randomized, double-blind, phase III study to evaluate efficacy and safety of HCP1803-4 in patients with essential hypertension
6,114 studies on the registry are indexed under Hypertension; 912 are open to participants now.
This study's planned enrollment of 256 is above the median of 100 across 4,575 interventional studies indexed under Hypertension.
Browse Hypertension studies →Hanmi Pharmaceutical Company Limited is the lead sponsor of 190 studies on the registry; 11 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 6 (55%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with essential hypertension whose blood pressure measured in visit1 corresponds to the following conditions
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Take HCP1803-3 once daily for 2 weeks orally, and then take HCP1803-4 once daily for 8 weeks orally.
Drug: HCP1803-3 · Drug: HCP1803-4
Take RLD2001-1 once daily for 2 weeks orally, and then take RLD2001-2 once daily for 8 weeks orally.
Drug: RLD2001-1 · Drug: RLD2001-2
Test drug
Test drug
Control drug
Control drug
Change from baseline in sitting systolic blood pressure
Time frame: Baseline, 10 weeks
Change from baseline in sitting systolic blood pressure
Time frame: Baseline, 2 weeks, 6 weeks
Change from baseline in sitting diastolic blood pressure
Time frame: Baseline, 2 weeks, 6 weeks, 10 weeks
Proportion of subjects achieving blood pressure control (sitSBP)
Time frame: 2 weeks, 6 weeks, 10 weeks
Proportion of subjects achieving blood pressure control (sitSBP, sitDBP)
Time frame: 2 weeks, 6 weeks, 10 weeks
Blood pressure response rate (sitSBP)
Time frame: 2 weeks, 6 weeks, 10 weeks
Blood pressure response rate (sitSBP, sitDBP)
Time frame: 2 weeks, 6 weeks, 10 weeks
Treatment response rate
Time frame: 2 weeks, 6 weeks, 10 weeks
Change from baseline in pulse pressure
Time frame: Baseline, 2 weeks, 6 weeks, 10 weeks
This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hanmi Pharmaceutical Company Limited →